Fabry Disease Global Market and Forecast to 2030

GURUGRAM, India - Aug. 5, 2025 - PRLog -- The global Fabry disease treatment market was valued at USD 2,215 Million in 2024, and is projected to reach USD 3,856 Million by 2030. Fabry disease is a rare genetic disorder resulting from a deficiency or malfunction of the enzyme called alpha-galactosidase A (α-GAL A). This enzyme is crucial for breaking down a type of fat called globotriaosylceramide (GL-3 or Gb3) in the body's cells. Without enough functional α-GAL A, this fat builds up, especially in blood vessels, kidneys, heart, and nerves, leading to progressive damage. The main objective of Fabry disease treatment is to minimize the buildup of globotriaosylceramide (Gb3) in the body, relieve associated symptoms, slow or prevent the progression of organ damage, and enhance patients' overall quality of life. The increasing number of patients suffering from Fabry disease and the escalating need for precise and effective therapies, such as enzyme replacement therapy, chaperone treatments, and substrate reduction therapy to stabilize individuals from suffering disease, are growth-inducing factors for the market.

For more details, please visit: https://apeloconsulting.com/product/fabry-disease-market-...